↓ Skip to main content

In vitro antineoplastic effects of auranofin in canine lymphoma cells

Overview of attention for article published in BMC Cancer, May 2018
Altmetric Badge

Mentioned by

3 tweeters


1 Dimensions

Readers on

8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
In vitro antineoplastic effects of auranofin in canine lymphoma cells
Published in
BMC Cancer, May 2018
DOI 10.1186/s12885-018-4450-2
Pubmed ID

Hong Zhang, Barbara J. Rose, Alex A. Pyuen, Douglas H. Thamm


The orally available gold complex auranofin (AF) has been used in humans, primarily as an antirheumatic/immunomodulatory agent. It has been safely administered to healthy dogs to establish pharmacokinetic parameters for oral administration, and has also been used as a treatment in some dogs with immune-mediated conditions. Multiple in vitro studies have recently suggested that AF may possess antineoplastic properties. Spontaneous canine lymphoma may be a very useful translational model for the study of human lymphoma, prompting the evaluation of AF in canine lymphoma cells. We investigated the antineoplastic activity of AF in 4 canine lymphoid tumor derived cell lines through measurements of proliferation, apoptosis, thioredoxin reductase (TrxR) activity and generation of reactive oxygen species (ROS), and detected the effects of AF when combined with conventional cytotoxic drugs using the Chou and Talalay method. We also evaluated the antiproliferative effects of AF in primary canine lymphoma cells using a bioreductive fluorometric assay. At concentrations that appear clinically achievable in humans, AF demonstrated potent antiproliferative and proapoptotic effects in canine lymphoid tumor cell lines. TrxR inhibition and increased ROS production was observed following AF treatment. Moreover, a synergistic antiproliferative effect was observed when AF was combined with lomustine or doxorubicin. Auranofin appears to inhibit the growth and initiate apoptosis in canine lymphoma cells in vitro at clinically achievable concentrations. Therefore, this agent has the potential to have near-term benefit for the treatment of canine lymphoma, as well as a translational model for human lymphoma. Decreased TrxR activity and increasing ROS production may be useful biomarkers of drug exposure.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 3 38%
Researcher 2 25%
Student > Ph. D. Student 1 13%
Student > Bachelor 1 13%
Other 1 13%
Other 0 0%
Readers by discipline Count As %
Veterinary Science and Veterinary Medicine 2 25%
Biochemistry, Genetics and Molecular Biology 2 25%
Agricultural and Biological Sciences 1 13%
Physics and Astronomy 1 13%
Chemistry 1 13%
Other 0 0%
Unknown 1 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 June 2018.
All research outputs
of 13,043,953 outputs
Outputs from BMC Cancer
of 4,865 outputs
Outputs of similar age
of 269,270 outputs
Outputs of similar age from BMC Cancer
of 1 outputs
Altmetric has tracked 13,043,953 research outputs across all sources so far. This one is in the 20th percentile – i.e., 20% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,865 research outputs from this source. They receive a mean Attention Score of 4.0. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 269,270 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them